These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18480209)

  • 1. Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer.
    Barry MJ; Kaufman DS; Wu CL
    N Engl J Med; 2008 May; 358(20):2161-8. PubMed ID: 18480209
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of prostate cancer with finasteride.
    Burke HB
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562806
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of prostate cancer with finasteride.
    Ross RK; Skinner E; Cote RJ
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562807
    [No Abstract]   [Full Text] [Related]  

  • 4. Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer.
    Kaufman DS; McDougal WS; Zietman AL; Young RH
    N Engl J Med; 2007 Jun; 356(24):2515-20. PubMed ID: 17568033
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemoprevention of prostate cancer.
    Walsh PC
    N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287
    [No Abstract]   [Full Text] [Related]  

  • 6. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer.
    Schlegel PN
    Curr Ther Endocrinol Metab; 1994; 5():543-50. PubMed ID: 7535663
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial.
    Walsh PC
    J Urol; 2006 Jul; 176(1):409-10; author reply 410. PubMed ID: 16753454
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of prostate cancer with finasteride.
    Barzell WE
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562803
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of prostate cancer with finasteride.
    Rubin MA; Kantoff PW
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14561801
    [No Abstract]   [Full Text] [Related]  

  • 14. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is tumour grade applicable to finasteride-treated prostate cancer?].
    Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
    Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
    Canby-Hagino E; Hernandez J; Brand TC; Thompson I
    Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade prostate cancer and the prostate cancer prevention trial.
    Logothetis CJ; Schellhammer PF
    Cancer Prev Res (Phila); 2008 Aug; 1(3):151-2. PubMed ID: 19138948
    [No Abstract]   [Full Text] [Related]  

  • 18. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of men on finasteride.
    Gormley GJ
    Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.